Stay updated with breaking news from Advicenne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Regulatory News: Advicenne (Euronext: ALDVI) (Paris:ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal
Regulatory News: The ordinary shareholders' meeting of Advicenne (Paris:ADVIC) (FR0013296746 ADVIC the "Company") held today, approved the proposed transfer of the listing of the Company's shares
18.01.2022 - Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces today sales of €3.3 million in ...